The use of bacteriophages as One-Health approach to reduce multidrug-resistant bacteria

Sustainable Chemistry and Pharmacy

Volumn 5, Issue , 2017, Pages 80-83

  Kittler, Sophie ^a   Wittmann, Johannes ^b   Mengden, Ruth Anna Lisa Perihan ^a   Klein, Günter ^a   Rohde, Christine ^b   Lehnherr, Hansjörg ^c  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^c PTC Phage Technology Center GmbH   (Germany)

Author keywords

Antimicrobial resistance; Bacteriophages; Multidrug resistant bacteria; One health

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIOPHAGE; HOST CELL; HOST RANGE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; WASTE MANAGEMENT; BACTERIAL LOAD; HEALTH CARE MANAGEMENT; KNOWLEDGE; ONE HEALTH APPROACH; TOTAL QUALITY MANAGEMENT;

EID: 84978901312     PISSN: None     EISSN: 23525541     Source Type: Journal    
DOI: 10.1016/j.scp.2016.06.001     Document Type: Article

References (45)

1. Aminov, R.I., A brief history of the antibiotic era: lessons learned and challenges for the future. Front. Microbiol., 1, 2010, 134.
2. Anand, T., Vaid, R.K., Bera, B., Barua, S., Riyesh, T., Virmani, N., Yadav, N., Malik, P., Isolation and characterization of a bacteriophage with broad host range, displaying potential in preventing bovine diarrhoea. Virus Genes 51 (2015), 315–321.
3. Bundesinstitut für Risikobewertung (BfR), 2014. Fragen und Antworten zu Methicillin-resistenten Staphylococcus aureus (MRSA) from 〈 http://www.bfr.bund.de/de/fragen_und_antworten_zu_methicillin_resistenten_staphylococcus_aureus__mrsa_-11172.html〉.
4. Bigwood, T., Hudson, J.A., Billington, C., Influence of host and bacteriophage concentrations on the inactivation of food-borne pathogenic bacteria by two phages. FEMS Microbiol. Lett. 291 (2009), 59–64.
5. Brandt, C., Makarewicz, O., Fischer, T., Stein, C., Pfeifer, Y., Werner, G., Pletz, M.W., The bigger picture: the history of antibiotics and antimicrobial resistance displayed by scientometric data. Int. J. Antimicrob. Agents 44 (2014), 424–430.
6. Brüssow, H., Canchaya, C., Hardt, W.D., Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol. Mol. Biol. Rev. 68 (2004), 560–602.
7. Carlton, R.M., Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. 47 (1999), 267–274.
8. Chee-Sanford, J.C., Mackie, R.I., Koike, S., Krapac, I.G., Lin, Y.F., Yannarell, A.C., Maxwell, S., Aminov, R.I., Fate and transport of antibiotic residues and antibiotic resistance genes following land application of manure waste. J. Environ. Qual. 38 (2009), 1086–1108.
9. Debarbieux, L., Pirnay, J.P., Verbeken, G., De Vos, D., Merabishvili, M., Huys, I., Patey, O., Schoonjans, D., Vaneechoutte, M., Zizi, M., Rohde, C., A bacteriophage journey at the European Medicines Agency. FEMS Microbiol. Lett., 363, 2016 225.
10. Dorman, L.C., Koeman, J., Nov. 13–15 2012. In: A One Health Approach to Antimicrobial Use & Resistance, Colorado Springs, CO, 80921.
11. EC, from 〈 http://eur-lex.europa.eu/legal-content/DE/TXT/?uri=CELEX%3A02003R1831-20151230〉, 2003.
12. FDA, from 〈http://www.fda.gov/OHRMS/DOCKETS/98fr/cf0559.pdf〉, 2006.
13. Fischer, S., Kittler, S., Klein, G., Glünder, G., Impact of a single phage and a phage cocktail application in broilers on reduction of Campylobacter jejuni and development of resistance. PLoS One, 8, 2013, e78543, 10.1371/journal.pone.0078543.
14. Gill, J.J., Hyman, P., Phage choice, isolation, and preparation for phage therapy. Curr. Pharm. Biotechnol. 11 (2010), 2–14.
15. Goodridge, L.D., Bisha, B., Phage-based biocontrol strategies to reduce foodborne pathogens in foods. Bacteriophage 1 (2011), 130–137.
16. Goossens, H., Ferech, M., Vander Stichele, R., Elseviers, M., Group, E.P., Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365 (2005), 579–587.
17. Grigoryan, L., Burgerhof, J.G., Degener, J.E., Deschepper, R., Lundborg, C.S., Monnet, D.L., Scicluna, E.A., Birkin, J., Haaijer-Ruskamp, F.M., consortium, S.A.R., Attitudes, beliefs and knowledge concerning antibiotic use and self-medication: a comparative European study. Pharmacoepidemiol. Drug Saf. 16 (2007), 1234–1243.
18. Hagens, S., Loessner, M.J., Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr. Pharm. Biotechnol. 11 (2010), 58–68.
19. Hegreness, M., Shoresh, N., Damian, D., Hartl, D., Kishony, R., Accelerated evolution of resistance in multidrug environments. Proc. Natl. Acad. Sci. USA 105 (2008), 13977–13981.
20. Jassim, S.A., Limoges, R.G., Natural solution to antibiotic resistance: bacteriophages'The Living Drugs’. World J. Microbiol. Biotechnol. 30 (2014), 2153–2170.
21. Kittler, S., Fischer, S., Abdulmawjood, A., Glünder, G., Klein, G., Effect of bacteriophage application on Campylobacter jejuni loads in commercial broiler flocks. Appl. Environ. Microbiol. 79 (2013), 7525–7533.
22. Kittler, S., Fischer, S., Abdulmawjood, A., Glünder, G., Klein, G., Colonisation of a phage susceptible Campylobacter jejuni population in two phage positive broiler flocks. PLoS One, 9, 2014, e94782, 10.1371/journal.pone.0094782.
23. Knoll, B.M., Mylonakis, E., Antibacterial bio-agents based on principles of bacteriophage biology – an overview. Clin. Infect. Dis. 58 (2013), 528–534.
24. Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., Abedon, S.T., Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11 (2010), 69–86.
25. Mapes, A.C., Trautner, B.W., Liao, K.S., Ramig, R.F., Development of expanded host range phage active on biofilms of multi-drug resistant Pseudomonas aeruginosa. Bacteriophage, 6, 2016, e1096995.
26. Meaden, S., Koskella, B., Exploring the risks of phage application in the environment. Front. Microbiol., 4, 2013, 358.
27. Międzybrodzki, R., Borysowski, J., Weber-Dabrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., Pawelczyk, Z., Rogoz, P., Klak, M., Wojtasik, E., Gorski, A., Clinical aspects of phage therapy. Adv. Virus Res. 83 (2012), 73–121.
28. Monk, A.B., Rees, C.D., Barrow, P., Hagens, S., Harper, D.R., Bacteriophage applications: where are we now?. Lett. Appl. Microbiol. 51 (2010), 363–369.
29. Oliver N. 8., Current developments and research in creating new antibiotics. Longev. Bull. (2016) pp. 20–23.
30. Ormala, A.M., Jalasvuori, M., Phage therapy: should bacterial resistance to phages be a concern, even in the long run?. Bacteriophage, 3, 2013, e24219.
31. Parracho, H.M., Burrowes, B.H., Enright, M.C., McConville, M.L., Harper, D.R., The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. Genet. Med. 6 (2012), 279–286.
32. Payne, R.J., Jansen, V.A., Pharmacokinetic principles of bacteriophage therapy. Clin. Pharmacokinet. 42 (2003), 315–325.
33. Piffaretti, J.C., Antibiotic resistance: the emergence of plasmid-mediated colistin resistance enhances the need of a proactive one-health approach. FEMS Microbiol. Lett., 363, 2016.
34. Pirnay, J.P., Blasdel, B.G., Bretaudeau, L., Buckling, A., Chanishvili, N., Clark, J.R., Corte-Real, S., Debarbieux, L., Dublanchet, A., De Vos, D., Gabard, J., Garcia, M., Goderdzishvili, M., Gorski, A., Hardcastle, J., Huys, I., Kutter, E., Lavigne, R., Merabishvili, M., Olchawa, E., Parikka, K.J., Patey, O., Pouilot, F., Resch, G., Rohde, C., Scheres, J., Skurnik, M., Vaneechoutte, M., Van Parys, L., Verbeken, G., Zizi, M., Van den Eede, G., Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32 (2015), 2173–2179.
35. Quinn, P.J., Markey, B.K., Leonard, F.C., FitzPatrick, E.S., Fanning, S., Hartigan, P.J., Veterinary Microbiology and Microbial Disease. 2nd Ed., 2011, Wiley Blackwell, Oxford, UK.
36. Tanji, Y., Shimada, T., Yoichi, M., Miyanaga, K., Hori, K., Unno, H., Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl. Microbiol. Biotechnol. 64 (2004), 270–274.
37. Thiel, K., Old dogma, new tricks – 21st Century phage therapy. Nat. Biotechnol. 22 (2004), 31–36.
38. Torres-Barcelo, C., Hochberg, M.E., Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol., 2016.
39. Verbeken, G., Pirnay, J.P., De Vos, D., Jennes, S., Zizi, M., Lavigne, R., Casteels, M., Huys, I., Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch. Immunol. Ther. Exp. 60 (2012), 161–172.
40. Weld, R.J., Butts, C., Heinemann, J.A., Models of phage growth and their applicability to phage therapy. J. Theor. Biol. 227 (2004), 1–11.
41. World Health Organization (WHO), 2011a. Race against time to develop new antibiotics, Bull. World Health Org. 89, pp. 88–98.
42. WHO, 2011b, Tackling Antibiotic Resistance From a Food Safety Perspective in Europe, 2100 Copenhagen, Denmark.
43. WHO, 2014. Antimicrobial Resistance Global Report on Surveillance, World Health Organization, Geneva, Switzerland.
44. WHO, 2015. Antimicrobial Resistance Fact sheet N°194 from 〈 http://www.who.int/mediacentre/factsheets/fs194/en/〉.
45. Yu, P., Mathieu, J., Li, M., Dai, Z., Alvarez, P.J., Isolation of polyvalent bacteriophages by sequential multiple-host approaches. Appl. Environ. Microbiol. 82 (2016), 808–815.